Vicore Pharma makes strategic recruitments

Vicore Pharma AB (publ) (ticker: VICO) today announced that they strengthen the organization with three new key recruitments.

Hans Jeppsson (Ph.D.) will be appointed Chief Financial Officer (CFO). Hans is a finance professional with cross-disciplinary background in finance and medicine in both academic and industry settings. He has several years of research experience in various fields, including small molecules and biologics. He did his post-doc research at University of California in Berkeley, CA. Hans has also worked as an equity research analyst at Danske Bank and has held different consulting roles. 

Ulrike Muscha Steckelings (M.D., Ph.D.) has been appointed Chief Scientific Officer (CSO).Muscha has been involved with Vicore Pharma and the company’s preclinical endeavors for more than 10 years, and she has been instrumental in the academic efficacy research on Vicore Pharma’s lead compound C21. She has extensive research experience in the fields of the Renin Angiotensin System and the AT2 receptor, and has published numerous articles in peer reviewed journals. She also holds a clinical degree in dermatology. Muscha maintains her position as a Professor of Integrative Pharmacology at University of Southern Denmark, Odense, in parallel with her role at Vicore Pharma.

Kicki Johansson (MSc Pharm Ph.D.) has been appointed Head of Drug Development. Kicki has been responsible for the development of more than 40 new compounds in different disease areas within Astra Zeneca. Most recently she has had a position as Senior Project Leader/VP for the development of oral anti-inflammatory projects within the Respiratory and Inflammatory Disease Division of AstraZeneca. 

“We are extremely happy to have Muscha, Kicki and Hans on board in Vicore Pharma. They provide both world class expertise in our field of research and experience with complex drug development and business development. All-in-all we have now built an exceptional team ahead of our clinical and business challenges”, says Per Jansson, CEO of Vicore Pharma.

For further information, please contact
Per Jansson, CEO
Tel: +46 709 17 47 46 or e-mail: per.jansson@vicorepharma.com 

This is information which Vicore Pharma Holding AB is required to disclose under the EU Market Abuse Regulation and the Securities Market Act. The information was provided by the above contact person's auspices, for publication June 1 at 11:00 CET

About Vicore Pharma Holding
Vicore Pharma, a Nasdaq Stockholm First North listed holding-, and management company. Vicore Pharma develops drugs targeting stimulation of the AT2 Receptor (AT2R) in the Renin-Angiotensin-System (RAS). The company vision is to establish AT2-agonists as a new effective class of small molecule drugs. Our lead candidate, C21 will be focused on the indication Idiopatic pulmonary fibrosis (IPF). For further information, please refer to www.vicorepharma.com

Vicore Pharmas share is listed on NASDAQ Stockholm, First North under the ticker VICO. The company´s Certified Adviser is Erik Penser Bank.


About Us

Vicore Pharma develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EU and the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. Vicore Pharma is based in Astra Zeneca's Bioventurehub in Mölndal. The company's share (VICO) is listed for trading on Nasdaq First North in Stockholm with Erik Penser Bank as Certified Adviser. For more information, see www.vicorepharma.com

Subscribe

Media

Media

Documents & Links